曲妥珠单抗联合化疗对HER2阳性晚期胃癌患者疗效及血清肿瘤标志物的影响  

Effect of Trastuzumab Combined with Chemotherapy on Efficacy and Serum Tumor Markers in Patients with HER2 Positive Advanced Gastric Cancer

作　　者：宋子正[1] 李靖华[1] 臧爱民[1] 杨华[1] 商琰红[1] 

机构地区：[1]河北大学附属医院,河北保定071000

出　　处：《中国药房》2016年第23期3249-3251,共3页China Pharmacy

摘　　要：目的:探讨曲妥珠单抗联合化疗对人表皮生长因子受体2(HER2)阳性晚期胃癌患者疗效及血清肿瘤标志物的影响。方法:将74例确诊为晚期胃癌且HER2呈阳性表达的患者根据入院先后顺序分为观察组和对照组,各37例。对照组患者接受顺铂+卡培他滨化疗;观察组患者在对照组治疗基础上,于化疗第1天加用曲妥珠单抗静脉滴注,8 mg/kg。21 d为1个周期,两组均治疗6个周期。比较两组患者的近期疗效、远期疗效、血清肿瘤标志物含量和毒副反应发生情况。结果:观察组患者的有效率(56.76%vs.32.44%)和控制率(89.19%vs.65.86%)均明显高于对照组,差异均有统计学意义(P<0.05);观察组患者的无进展生存时间、中位生存时间均明显长于对照组,差异均有统计学意义(P<0.05);观察组患者的血清癌胚抗原、糖类抗原(CA)199、CA724含量均明显低于对照组,差异均有统计学意义(P<0.05)。两组患者的恶心呕吐、肝功能损害、骨髓抑制、手足综合征等毒副反应发生率比较,差异均无统计学意义(P>0.05)。结论:曲妥珠单抗联合化疗有助于降低血清肿瘤标志物含量,改善HER2阳性晚期胃癌患者的近期疗效和远期疗效。OBJECTIVE：To discuss the effect of trastuzumab combined with chemotherapy on efficacy and serum tumor markers in patients with human epidermal growth factor receptor 2（HER2）positive advanced gastric cancer. METHODS：74 advanced gastric cancer patients in HER2 positive were randomly divided into observation group and control group,37 cases in each group.Control group received cisplatin ＋ capecitabine chemotherapy;based on it,observation group additionally received trastuzumab by intravenous infusion in the first day,8 mg/kg. 21 d was a course,and it lasted for 6 months. The short-term efficacy,long-term efficacy,serum tumor marker contents and toxic and side effects were compared between 2 groups. RESULTS：The effective rate（56.76% vs. 32.44%）and control rate（89.19% vs. 65.86%）in observation group were significantly higher than control group,the differences were statistically significant（P〈0.05）;progression-free survival time and median survival time in observation group significantly longer than control group,the differences were statistically significant（P〈0.05）;contents of serum carcinoembryonic antigen,carbohydrate antigen（CA）199,CA724 in observation group significantly lower than control group,the differences were statistically significant（P〈0.05）. And there were no significant differences in the incidences of nausea and vomiting,liver damage,bone marrow suppression and hand-foot syndrome in 2 groups（P〉0.05）. CONCLUSIONS：Trastuzumab combined with chemotherapy helps to reduce serum tumor markers content,and improve short-term efficacy,long-term efficacy of advanced gastric cancer patients with positive HER2.

关 键 词：曲妥珠单抗 人表皮生长因子受体2 晚期胃癌 血清肿瘤标志物 

分 类 号：R735.2[医药卫生—肿瘤]